Project Grant R01DK143945
Award Date 8/1/26
Completion Date 5/31/30
Dollars Obligated $672K
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $670,268 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate cholangiocyte-driven proinflammatory signaling in primary sclerosing cholangitis (PSC). The research employs spatial analysis of human PSC liver tissues and murine disease models to define how cholangiocytes engage the innate immune system via neutrophil recruitment and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $802,715 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate pathogen-induced biliary inflammation in sclerosing cholangiopathies, particularly primary sclerosing cholangitis (PSC). The research examines how biliary epithelial cells respond to gut-derived pathobionts, pathogen-associated molecular patterns, and pro-inflammatory...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $495,130 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate autophagic processes and hepatocellular steatosis. The award funds research into the mechanisms by which hepatocytes regulate lipid droplet storage, breakdown, and catabolism in metabolic dysfunction-associated steatotic liver disease (MASLD). The research focuses on two...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Regents of the University of California, San Francisco $626,188 on May 15, 2026, to develop a therapy for human cholestatic liver diseases based on hepatocyte plasticity. The research aims to investigate how hepatocyte plasticity—the ability of liver cells to assume a biliary identity and form functional bile ducts—can be harnessed therapeutically in diseases including Alagille Syndrome and primary sclerosing...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Virginia Commonwealth University $352,242 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of the transcription factor RUNX1 in cholangiocyte signaling and biliary fibrosis. The project will examine how RUNX1 coordinates transcriptomic and lipidomic programs in cholangiocytes activated by transforming growth factor-beta, with...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded La Jolla Institute for Immunology $939,776 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of mucosal associated invariant T (MAIT) cells in primary biliary cholangitis pathogenesis. The project analyzes immune and genetic mechanisms underlying primary biliary cholangitis, an autoimmune liver disease characterized by immune-mediated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $149,190 on September 30, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis. The funded research investigates novel mechanisms driving liver fibrosis progression to guide development of potential treatment strategies. The project tests the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $550,070 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research elucidating ATP8B1 deficiency using patient-derived induced pluripotent stem cell (iPSC) models. The project addresses progressive familial intrahepatic cholestasis (PFIC) caused by ATP8B1 mutations, a rare inherited liver disease that impairs bile...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Cincinnati Children's Hospital Medical Center $851,275 on February 15, 2026, to investigate mechanisms regulating hepatocyte plasticity and competency for reprogramming into cholangiocytes as a potential therapeutic approach for intrahepatic bile duct paucity. The research addresses the scientific barrier that hepatocytes in cholestatic stress can reprogram to form functional intrahepatic bile duct networks, but key...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded a cooperative agreement to Mayo Clinic on September 22, 2025, for $561,335 to establish and operate the Mayo Clinic Polycystic Kidney Disease Research Core Center (MPRC), which provides reagents, biological materials, phenotyping data, and expertise to the polycystic kidney disease research community through the PKD-Research Resource Consortium. The MPRC operates three cores. The Human ADPKD Population and Materials...